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Germ cell tumors are the most common malignancy in men aged 15-35 years old, with a small per-
centage presenting in an extragonadal location. These tumors are seldom identiﬁed in the gastrointes-
tinal tract. There is increased risk of extragonadal germ cell tumors (EGCT) in men with Klinefelter
syndrome (KS). We report a rare case of a 37-year-old male with KS and EGCT discovered in the duo-
denum and pelvis. After treatment with Bleomycin-Etoposide-Cisplatin (BEP), he developed growing
teratoma syndrome (GTS) and myelodysplasia. Despite surgical excision of the pelvic growing teratoma,
he unfortunately died secondary to complications of severe bone marrow suppression.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Germ cell tumors are the most common malignancy in the
testicle, and the most common malignancy in males 15-35 years
old.1 It is reported that 5% of germ cell tumors are extragonadal.1
Men with Klinefelter syndrome (KS) have an increased risk of
developing extragonadal germ cell tumors (EGCT), though the
overall risk has not warranted routine screening in the KS popu-
lation.2 Themost common primary site of EGCT is the mediastinum,
followed by the retroperitoneum.1 Literature has described cases of
EGCTs located in the pineal gland, presacral area, bladder, prostate,
and liver.1 To our knowledge, there has never been a published case
of EGCT of gastrointestinal origin. We report a case of a patient with
KS and EGCT of duodenal origin.Case presentation
A 37-year-old male presented with nausea, vomiting, abdominal
pain, weight loss, and symptoms of gastroesophageal reﬂux disease
despite medical management. Computed tomography (CT)
demonstrated a 16 cm distal gastric mass and a 7 cm pelvic mass
(Fig. 1AeC). Biopsy of the gastric mass was nondiagnostic.om funding agencies in the
onheim).
Inc. This is an open access article uEsophagogastroduodenoscopy identiﬁed amass at the distal pyloric
region of the stomach suggestive of a hemangioma, but was not
biopsied due to concern for bleeding. An exploratory laparotomy
was performed with resection of abdominal mass, partial gastrec-
tomy, partial hepatectomy, and a roux-en-y gastroduodenostomy.
Pathologic analysis demonstrated mixed germ cell tumor with
components of immature teratoma and yolk sac tumor, consistent
with extragonadal nonseminomatous germ cell tumor (NSGCT).
The patient was referred to Louisiana State University Department
of Urology for further evaluation. On physical examination, he was
tall with long limbs, and had bilaterally descended small atrophic
testicles with no masses. Tumor markers were: b-hCG 13 (<5), AFP
10511 (<15), and LDH 247 (<201). Karyotypewas performed, which
diagnosed Klinefelter syndrome (47 XXY). A scrotal ultrasound
revealed small (<1 cc) testes bilaterally with no masses. Staging CT
of the chest, abdomen, and pelvis was signiﬁcant for an
8.4  7.0  5.6 cm pelvic mass, mild right hydroureteronephrosis,
bilateral pelvic lymphadenopathy >1 cm, T11 vertebral body frac-
ture, and mediastinal lymphadenopathy >1 cm. Magnetic reso-
nance imaging (MRI) of the brain was negative for metastasis. Bone
scan was performed, which demonstrated a T11 lytic lesion con-
cerning for pathologic compression fracture (Fig. 2). This staged the
patient as cTxN1M1bS3 nonseminomatous EGCT, Stage IIIC, with
poor prognostic features. The patient was treatedwith four cycles of
Bleomycin-Etoposide-Cisplatin (BEP) chemotherapy per NCCN
guidelines. Tumor markers, repeated after chemotherapy, had
normalized. Postchemotherapy imaging demonstrated disease
progression despite chemotherapy, with interval progression fromnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. CT abdomen/pelvis on initial presentation, axial (A,B) and coronal (C). These images demonstrate the duodenal mass (A, C), and the pelvic mass (B), which were identiﬁed
at presentation, the red arrows point to the “duodenal mass,” and “pelvic mass”.
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tastases (Fig. 3A). The pelvic/retroperitoneal mass was consistent
with growing teratoma syndrome (GTS).3 Additionally, the patient
developed myelodysplasia secondary to treatment, with severe
thrombocytopenia (Platelet counts < 5000). MRI of the pelvis was
performed for surgical planning (Fig. 3B). Despite his severe
thrombocytopenia, he underwent extirpation of the pelvic/retro-
peritoneal growing teratoma, right seminal vesicle, and right distal
ureter. Concomitant psoas hitch and ureteral reimplantation was
performed. Pathologic analysis demonstrated mature teratoma,
consistent with GTS. The patient had an uncomplicated immediate
postoperative course and was discharged home on postoperative
day ﬁve. Unfortunately, the patient continued to experience pro-
gressive bone marrow suppression, and was unable to receive
further therapy. Patient died secondary to progression of his disease
and severe bone marrow suppression 5 months later.Figure 2. Bone scan demonstrating T11 lesion, the red arrow points to the “T11 lesion”.Discussion
Extragonadal germ cell tumors have been identiﬁed in a variety
of anatomical locations.1,4 Incidence of EGCT in abdominal viscera,
such as the duodenum, is very rare.1 Unfortunately, there is very
little referenced in the literature about abdominal visceral EGCT.
Knowledge is therefore extrapolated from mediastinal and retro-
peritoneal EGCT, which are the most common sites of disease. As
compared with seminomatous EGCT, nonseminomatous ECGT have
worse prognosis, with a 5-year survival rate of 62% for retroperi-
toneal and 45% for mediastinal.1 Presence of a nonpulmonary
visceral metastasis or primary tumor location other than testicle
Figure 3. CT (A) and MRI (B) after BEP  4 cycles, demonstrating growing teratoma the red arrows point to the “growing teratoma”.
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national Germ Cell Cancer Collaboration Group (IGCCCG) classiﬁ-
cation of poor prognosis. This group has a 5-year survival rate of
48%.5 Surgery is an integral component of treatment of EGCT due to
the risk of residual viable tumor. In one series, after secondary
surgery, 25% of patients with nonseminomatous retroperitoneal
EGCT had viable undifferentiated tumor in the specimen, and 16%
had major teratoma.1 Additionally, surgical excision is the treat-
ment of choice in the setting of GTS. GTS is deﬁned as enlarging
retroperitoneal mass or metastatic lesion during systemic chemo-
therapy for NSGCT, with normalization of tumor markers, and
predominance of mature teratoma in resected specimen.3 In cases
with partial remission or disease progression after resection, there
is a role for salvage chemotherapy. The median survival time for
patients requiring salvage chemotherapy after relapse was 11-
15 months.1
In addition to the poor prognostic factors, the patient also
developedmyelodysplasiawith severe thrombocytopenia and bone
marrow suppression. Patients with nonseminomatous mediastinal
EGCT have a known increased risk of developing acute mega-
karyoblastic leukemia and myelodysplasia with abnormal mega-
karyocytes.1 This is seen in 2% of patients, which is 250 times
greater incidence as compared to the general population.1 After
development of hematologic malignancy, median survival is
approximately 5-6 months despite efforts to treat.1 We intended to
perform further site-directed excisions of his likely multiple
growing teratomas after improved control of his thrombocytopeniaand possibly salvage chemotherapy. Unfortunately, the patient was
never able to tolerate these treatments, and succumbed to com-
plications of his disease 5 months after surgery.
Conclusion
We report a rare case of EGCT and GTS in a male with KS who
initially presented with a duodenal mass, which has not been
described in the literature. Unfortunately in this patient with GTS,
he was unable to reach complete resection due to severe compli-
cations of chemotherapy and of his disease, ultimately resulting in
his death.
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